A Guide to Selecting High-performing Antibodies for Serine/threonine-protein Phosphatase 2A 56 KDa Regulatory Subunit Delta Isoform (PPP2R5D) for Use in Western Blot, Immunoprecipitation and Immunofluorescence

Overview

Journal F1000Res

Specialties Biomedical Engineering
Science

Date 2025 Feb 12

PMID 39935523

Authors

Riham Ayoubi

Maryam Fotouhi

Charles Alende

Kathleen Southern

Carl Laflamme

Affiliations

Soon will be listed here.

Abstract

Protein phosphatase 2A is a serine/threonine phosphatase with activity dependent on an associated regulatory subunit, serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit delta (δ) isoform (PPP2R5D). PPP2R5D is the δ isoform in the B56 family of regulatory subunits. Abundantly expressed in the brain and involved in a broad range of cellular processes, PPP2R5D plays an essential role in modulating key neuronal pathways and signalling. Pathogenic mutations in the gene are linked to clinical symptoms characterized by neurodevelopmental delay, intellectual disability, and autism spectrum disorders. The etiology of these genetic disorders remains unknown, which can partly be due to the lack of independently characterized antibodies. Here we have characterized six PPP2R5D commercial antibodies for Western Blot, immunoprecipitation, and immunofluorescence using a standardized experimental protocol based on comparing read-outs in knockout cell lines and isogenic parental controls. These studies are part of a larger, collaborative initiative seeking to address antibody reproducibility by characterizing commercially available antibodies for human proteins and publishing the results openly as a resource for the scientific community. While use of antibodies and protocols vary between laboratories, we encourage readers to use this report as a guide to select the most appropriate antibodies for their specific needs.

References

Louis J, Martens E, Borghgraef P, Lambrecht C, Sents W, Longin S . Mice lacking phosphatase PP2A subunit PR61/B'delta (Ppp2r5d) develop spatially restricted tauopathy by deregulation of CDK5 and GSK3beta. Proc Natl Acad Sci U S A. 2011; 108(17):6957-62. PMC: 3084077. DOI: 10.1073/pnas.1018777108. View

Carter A, Kraemer O, Zwick M, Mueller-Fahrnow A, Arrowsmith C, Edwards A . Target 2035: probing the human proteome. Drug Discov Today. 2019; 24(11):2111-2115. DOI: 10.1016/j.drudis.2019.06.020. View

Bandrowski A, Pairish M, Eckmann P, Grethe J, Martone M . The Antibody Registry: ten years of registering antibodies. Nucleic Acids Res. 2022; 51(D1):D358-D367. PMC: 9825422. DOI: 10.1093/nar/gkac927. View

McCright B, Brothman A, Virshup D . Assignment of human protein phosphatase 2A regulatory subunit genes b56alpha, b56beta, b56gamma, b56delta, and b56epsilon (PPP2R5A-PPP2R5E), highly expressed in muscle and brain, to chromosome regions 1q41, 11q12, 3p21, 6p21.1, and 7p11.2 --> p12. Genomics. 1996; 36(1):168-70. DOI: 10.1006/geno.1996.0438. View

Eichhorn P, Creyghton M, Bernards R . Protein phosphatase 2A regulatory subunits and cancer. Biochim Biophys Acta. 2008; 1795(1):1-15. DOI: 10.1016/j.bbcan.2008.05.005. View

Kamibayashi C, Estes R, Lickteig R, Yang S, Craft C, Mumby M . Comparison of heterotrimeric protein phosphatase 2A containing different B subunits. J Biol Chem. 1994; 269(31):20139-48. View

Gilissen C, Hehir-Kwa J, Tjwan Thung D, van de Vorst M, van Bon B, Willemsen M . Genome sequencing identifies major causes of severe intellectual disability. Nature. 2014; 511(7509):344-7. DOI: 10.1038/nature13394. View

Ronne H, Carlberg M, Hu G, Nehlin J . Protein phosphatase 2A in Saccharomyces cerevisiae: effects on cell growth and bud morphogenesis. Mol Cell Biol. 1991; 11(10):4876-84. PMC: 361456. DOI: 10.1128/mcb.11.10.4876-4884.1991. View

Abrahams B, Arking D, Campbell D, Mefford H, Morrow E, Weiss L . SFARI Gene 2.0: a community-driven knowledgebase for the autism spectrum disorders (ASDs). Mol Autism. 2013; 4(1):36. PMC: 3851189. DOI: 10.1186/2040-2392-4-36. View

10.

Janssens V, Goris J . Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J. 2001; 353(Pt 3):417-39. PMC: 1221586. DOI: 10.1042/0264-6021:3530417. View

11.

Stessman H, Xiong B, Coe B, Wang T, Hoekzema K, Fenckova M . Targeted sequencing identifies 91 neurodevelopmental-disorder risk genes with autism and developmental-disability biases. Nat Genet. 2017; 49(4):515-526. PMC: 5374041. DOI: 10.1038/ng.3792. View

12.

Stringer C, Wang T, Michaelos M, Pachitariu M . Cellpose: a generalist algorithm for cellular segmentation. Nat Methods. 2020; 18(1):100-106. DOI: 10.1038/s41592-020-01018-x. View

13.

de Ligt J, Willemsen M, van Bon B, Kleefstra T, Yntema H, Kroes T . Diagnostic exome sequencing in persons with severe intellectual disability. N Engl J Med. 2012; 367(20):1921-9. DOI: 10.1056/NEJMoa1206524. View

14.

Basu S, Kollu R, Banerjee-Basu S . AutDB: a gene reference resource for autism research. Nucleic Acids Res. 2008; 37(Database issue):D832-6. PMC: 2686502. DOI: 10.1093/nar/gkn835. View

15.

Iossifov I, ORoak B, Sanders S, Ronemus M, Krumm N, Levy D . The contribution of de novo coding mutations to autism spectrum disorder. Nature. 2014; 515(7526):216-21. PMC: 4313871. DOI: 10.1038/nature13908. View

16.

Biswas D, Cary W, Nolta J . PPP2R5D-Related Intellectual Disability and Neurodevelopmental Delay: A Review of the Current Understanding of the Genetics and Biochemical Basis of the Disorder. Int J Mol Sci. 2020; 21(4). PMC: 7072873. DOI: 10.3390/ijms21041286. View

17.

Shang L, Henderson L, Cho M, Petrey D, Fong C, Haude K . De novo missense variants in PPP2R5D are associated with intellectual disability, macrocephaly, hypotonia, and autism. Neurogenetics. 2015; 17(1):43-9. PMC: 4765493. DOI: 10.1007/s10048-015-0466-9. View

18.

Glenn G, Eckhart W . Mutation of a cysteine residue in polyomavirus middle T antigen abolishes interactions with protein phosphatase 2A, pp60c-src, and phosphatidylinositol-3 kinase, activation of c-fos expression, and cellular transformation. J Virol. 1993; 67(4):1945-52. PMC: 240262. DOI: 10.1128/JVI.67.4.1945-1952.1993. View

19.

Laflamme C, McKeever P, Kumar R, Schwartz J, Kolahdouzan M, Chen C . Implementation of an antibody characterization procedure and application to the major ALS/FTD disease gene C9ORF72. Elife. 2019; 8. PMC: 6794092. DOI: 10.7554/eLife.48363. View

20.

Satterstrom F, Kosmicki J, Wang J, Breen M, De Rubeis S, An J . Large-Scale Exome Sequencing Study Implicates Both Developmental and Functional Changes in the Neurobiology of Autism. Cell. 2020; 180(3):568-584.e23. PMC: 7250485. DOI: 10.1016/j.cell.2019.12.036. View